Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Capital Expenditures (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Capital Expenditures data on record, last reported at $28.4 million in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 21.07% year-over-year to $28.4 million; the TTM value through Dec 2025 reached $34.9 million, down 15.01%, while the annual FY2025 figure was $34.9 million, 15.01% down from the prior year.
  • Capital Expenditures reached $28.4 million in Q4 2025 per AMPH's latest filing, up from -$14.7 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $35.9 million in Q4 2024 and bottomed at -$14.7 million in Q3 2025.
  • Average Capital Expenditures over 5 years is $5.7 million, with a median of $5.4 million recorded in 2022.
  • Peak YoY movement for Capital Expenditures: skyrocketed 85626.19% in 2024, then tumbled 815.16% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $6.9 million in 2021, then plummeted by 73.47% to $1.8 million in 2022, then crashed by 102.3% to -$42000.0 in 2023, then surged by 85626.19% to $35.9 million in 2024, then decreased by 21.07% to $28.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $28.4 million in Q4 2025, -$14.7 million in Q3 2025, and $10.6 million in Q2 2025.